Subcutaneous · GLP-1 agonist
CJC-1134-PC
5 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
5
Ongoing
0
Recruiting
0
Completed
4
Sites
25
Countries
3
Endpoints
55
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 2
3
Phase 3
2
Trials by status
Completed
4
Terminated
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Glycemic / diabetes
26
Cardiometabolic biomarkers
14
Weight & body composition
9
MASH / liver
4
Other (unclassified)
2
Top 20 metrics across this asset's endpoints
HbA1c, changeGlycemic
1
Body weight, absolute change (kg)Weight
1
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
5 of 5
Showing 1-5 of 5 trials